Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook [Yahoo! Finance]
Valneva SE - American Depositary Shares (VALN)
Company Research
Source: Yahoo! Finance
Excluding COVID-19 vaccine sales, product sales grew by 63% compared to 2022 Cash position of €126.1 million at year-end 2023 enhanced by €95 million from sale of Priority Review Voucher (PRV) Extended the interest-only period of existing debt financing agreement to January 2026 significantly extending cash runway Operational business considered sufficiently funded (excluding debt repayment) until commercial revenues from Lyme program enable sustained profitability Excellent progress across R&D pipeline Approval of single-shot chikungunya vaccine IXCHIQ ® in the United States (U.S.) The world's first and only vaccine to address this significant unmet medical need U.S. CDC recently adopted ACIP recommendations Regulatory reviews ongoing in Europe, Canada and Brazil Completion of recruitment for Lyme disease Phase 3 study conducted in collaboration with Pfizer All execution milestones on track Advancing second-generation ZIKA vaccine candidate into Phase 1 clinica
Show less
Read more
Impact Snapshot
Event Time:
VALN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VALN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VALN alerts
High impacting Valneva SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VALN
News
- Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate [Yahoo! Finance]Yahoo! Finance
- Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine CandidateGlobeNewswire
- Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F [Yahoo! Finance]Yahoo! Finance
- Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-FGlobeNewswire
- Valneva SE (NASDAQ: VALN) had its price target lowered by analysts at Guggenheim from $18.00 to $17.00. They now have a "buy" rating on the stock.MarketBeat
VALN
Sec Filings
- 3/26/24 - Form 6-K
- 3/22/24 - Form 20-F
- 3/22/24 - Form 6-K
- VALN's page on the SEC website